Recent studies demonstrate that PTK7-neutralizing monoclonal antibodies (mAbs) inhibit VEGF-induced angiogenesis, block KDR activation, and decrease proliferation and migration in ESCC models [29]. This evidence concerns the gene PTK7 and esophageal squamous cell carcinoma.